Overcoming Ovarian Cancer Chemoresistance

Overcoming Ovarian Cancer Chemoresistance
Author: Goli Samimi,Christina Annunziata
Publsiher: Academic Press
Total Pages: 188
Release: 2020-11-06
ISBN 10: 0128198419
ISBN 13: 9780128198414
Language: EN, FR, DE, ES & NL

Overcoming Ovarian Cancer Chemoresistance Book Review:

Overcoming Ovarian Cancer Chemoresistance presents non-overlapping review chapters that discuss the state of the field in overcoming chemoresistance of ovarian cancer and treatment options before and following recurrence, considering the genetic makeup of the ovarian cancer patient and her tumor. With the uptake of both germline and somatic gene testing, clinicians can obtain a more comprehensive understanding of ovarian tumors and this book provides information to link the genetic makeup of a tumor (or patient) with the best available treatment. The book discusses topics such as strategies to fight chemo-resistance in ovarian cancer, circulating DNA as a monitor of response, BRCA mutations, ovarian cancer stem cells, immunotherapy and vaccines. Additionally, it brings a list of promising agents at clinical and pre-clinical stage that will impact the treatment in the near future. This book is a valuable source for cancer researchers, oncologists and several members of biomedical field who need to understand how to battle chemoresistance in ovarian cancer. Provides a comprehensive view of both biological and genetic determinants of resistance, as well as technical approaches to monitor response Discusses genetic reversions as a unique alteration and a new field of study Includes a chapter on upcoming and promising agents that are in the pre-clinical and early clinical space, to set the stage for future directions in the field

Overcoming Drug Resistance in Gynecologic Cancers

Overcoming Drug Resistance in Gynecologic Cancers
Author: Anonim
Publsiher: Academic Press
Total Pages: 388
Release: 2021-08-11
ISBN 10: 0128243007
ISBN 13: 9780128243008
Language: EN, FR, DE, ES & NL

Overcoming Drug Resistance in Gynecologic Cancers Book Review:

Overcoming Drug Resistance in Gynecologic Cancers provides up-to-date information related to important gynecologic cancers and focuses on mechanisms of drug resistance, genetics, signaling, immunology, health disparities, nanotechnology, economic considerations and financial impacts. The book covers not only drug resistance but also important means to reverse resistance both in the laboratory and clinic. The book discusses topics such as lifestyle, nutrition and risk of gynecologic cancers, the financial impact of drug resistance, chemosensitizing agents and targeted therapies in cervical, endometrial and ovarian cancer, immunotherapy to overcome drug resistance, and genetic polymorphisms in gynecologic cancers. Additionally, it discusses ethnic and racial health disparity perspectives and future developments in chemosensitizing activities to reverse drug resistance in gynecologic cancers. It is a valuable resource for cancer researchers, oncologists, clinicians and other biomedical field members who are interested in new approaches to improve chemotherapy outcome in patients with gynecologic cancers. Provides a comprehensive resource with all the details needed for readers to understand and follow information Encompasses schematics, diagrams and flow charts in all chapters to help readers easily follow critical information Presents tables and figures especially developed to summarize the information with appropriate statistical rigor and to show details of clinical specimens such as pathological, radiological characteristics, and/or laboratory biomarkers

Cancer Cell Chemoresistance And Chemosensitization

Cancer Cell Chemoresistance And Chemosensitization
Author: Kunnumakkara Ajaikumar B,Bordoloi Devivasha,Monisha Javadi
Publsiher: World Scientific
Total Pages: 684
Release: 2018-02-13
ISBN 10: 9813208589
ISBN 13: 9789813208582
Language: EN, FR, DE, ES & NL

Cancer Cell Chemoresistance And Chemosensitization Book Review:

Despite the significant advances in cancer therapy made through constant evaluation and analysis of treatment aftereffects, the disease still remains one of the foremost causes of mortality worldwide killing more than 12 million people annually. The prime reason behind the failure of conventional chemotherapeutics which are used as the chief regimen in the comprehensive treatment of cancers is the development of chemoresistance. It can be either intrinsic or acquired and is primarily mediated via different key regulators like MDR, MAPK, NF-κB, PI3K/Akt, Wnt signaling pathways etc. Thus, agents which can target these regulatory elements or pathways and in turn sensitize cancer cells to chemotherapy holds immense prospect. However, there is barely such comprehensive work available in scientific literature that explains how chemosensitization of cancer cells functions using different drug combinations and exhibit synergism. This book provides a detailed description of chemoresistance and chemosensitization, targets for chemosensitization and various approaches adapted in the process of chemosensitization. Furthermore, the book explicates the role of various chemosensitizers, both natural and synthetic in sensitizing cancer cells and also details the current research findings on chemosensitization of different cancer types in both pre-clinical and clinical settings. Contents: Introduction and Basic Concepts of Cancer (Devivasha Bordoloi, Bethsebie Lalduhsaki Sailo, Nafiseh Manteghi, Ganesan Padmavathi and Ajaikumar B Kunnumakkara ) Cancer Cell Chemoresistance: A Prime Obstacle in Cancer Therapy (Javadi Monisha, Aviral Jaiswal, Kishore Banik, Harsha Choudhary, Anuj Kumar Singh, Devivasha Bordoloi and Ajaikumar B Kunnumakkara) Bladder Cancer: Chemoresistance and Chemosensitization (Nand Kishor Roy, Anand Sharma, Anuj Kumar Singh, Devivasha Bordoloi, Bethsebie Lalduhsaki Sailo, Javadi Monisha and Ajaikumar B Kunnumakkara) Mechanism of Chemoresistance in Bone Cancer and Different Chemosensitization Approaches (Ganesan Padmavathi, Devivasha Bordoloi, Kishore Banik, Javadi Monisha, Anuj Kumar Singh and Ajaikumar B Kunnumakkara) Chemoresistance in Brain Cancer and Different Chemosensitization Approaches (Amrita Devi Khwairakpam, Javadi Monisha, Kishore Banik, Harsha Choudhary, Anand Sharma, Devivasha Bordoloi and Ajaikumar B Kunnumakkara) Phytochemicals as Chemosensitizers in Breast Cancer (Madhumita Roy, Ruma Sarkar, Apurba Mukherjee, Sutapa Mukherjee and Jaydip Biswas) Potential of Different Chemosensitizers to Overcome Chemoresistance in Cervical Cancer (Kishore Banik, Bethsebie Lalduhsaki Sailo, Krishan Kumar Thakur, Aviral Jaiswal, Javadi Monisha, Devivasha Bordoloi and Ajaikumar B. Kunnumakkara) Colon Cancer Chemoresistance and Chemosensitization (Muthu K Shanmugam, Arunasalam Dharmarajan, Frank Arfuso and Gautam Sethi) Cancer Cell Chemoresistance and Chemosensitization in Endometrial Cancer (Anuj Kumar Singh, Javadi Monisha, Kishore Banik, Harsha Choudhary, Amrita Devi Khwairakpam, Devivasha Bordoloi and Ajaikumar B Kunnumakkara) Different Approaches to Overcome Chemoresistance in Esophageal Cancer (Devivasha Bordoloi, Kishore Banik, Amrita Devi Khwairakpam, Anand Sharma, Javadi Monisha, Bethsebie Lalduhsaki Sailo and Ajaikumar B Kunnumakkara) Different Chemosensitization Approaches in Gastric Cancer (Harsha Choudhary, Devivasha Bordoloi, Jai Prakash, Nafiseh Manteghi, Ganesan Padmavathi, Javadi Monisha and Ajaikumar B Kunnumakkara) Chemoresistance and Chemosensitization in Hematological Malignancies (Ota Fuchs) Different Methods to Inhibit Chemoresistance in Hepatocellular Carcinoma (Anuj Kumar Singh, Nand Kishor Roy, Anand Anip, Kishore Banik, Javadi Monisha, Devivasha Bordoloi

Cancer Cell Chemoresistance and Chemosensitization

Cancer Cell Chemoresistance and Chemosensitization
Author: Ajaikumar B. Kunnumakkara,Devivasha Bordoloi,Javadi Monisha
Publsiher: World Scientific
Total Pages: 135
Release: 2018
ISBN 10: 9813208570
ISBN 13: 9789813208575
Language: EN, FR, DE, ES & NL

Cancer Cell Chemoresistance and Chemosensitization Book Review:

Epigenetic Regulation in Overcoming Chemoresistance

Epigenetic Regulation in Overcoming Chemoresistance
Author: Chunfu Wu,Lihui Wang
Publsiher: Academic Press
Total Pages: 144
Release: 2021-06-26
ISBN 10: 012823685X
ISBN 13: 9780128236857
Language: EN, FR, DE, ES & NL

Epigenetic Regulation in Overcoming Chemoresistance Book Review:

Epigenetic Regulation in Overcoming Chemoresistance, Volume 19, explains how epigenetic agents can enhance the chemotherapy sensitivity of diverse types of cancers. The book provides a comprehensive delineation and the recent development of the scientific studies on the epigenetic regulation in enhancing chemo-sensitivity. In addition, it discusses several topics such as DNA methyltransferase inhibitors (DNMTi), Histone deacetylases inhibitors (HDACi), Histone lysine demethylases inhibitors (HDMi), Histone lysine methyltransferases inhibitors (HMTi) and drugs regulating the microRNA, long non-coding RNA (lncRNA) or RNA methylation. Finally, recent and future developments of the field of epigenetic regulation are explored. This is a valuable resource for cancer researchers, clinicians, graduate students and several members of biomedical field who are interested in learning about epigenetic regulation methods to reverse chemo-resistance in cancers. Presents detailed diagrams of the mechanisms of epigenetic regulation for easy consult Encompasses multiple clinical trial summary diagrams to help readers quickly and clearly get information from clinical trials Provides future perspectives in each section to inspire readers to use epigenetic regulation to overcome chemo-resistance

Overcoming Drug Resistance in Gynecologic Cancers

Overcoming Drug Resistance in Gynecologic Cancers
Author: Anonim
Publsiher: Elsevier
Total Pages: 388
Release: 2021-09-03
ISBN 10: 012824299X
ISBN 13: 9780128242995
Language: EN, FR, DE, ES & NL

Overcoming Drug Resistance in Gynecologic Cancers Book Review:

Overcoming Drug Resistance in Gynecologic Cancers provides up-to-date information related to important gynecologic cancers and focuses on mechanisms of drug resistance, genetics, signaling, immunology, health disparities, nanotechnology, economic considerations and financial impacts. The book covers not only drug resistance but also important means to reverse resistance both in the laboratory and clinic. The book discusses topics such as lifestyle, nutrition and risk of gynecologic cancers, the financial impact of drug resistance, chemosensitizing agents and targeted therapies in cervical, endometrial and ovarian cancer, immunotherapy to overcome drug resistance, and genetic polymorphisms in gynecologic cancers. Additionally, it discusses ethnic and racial health disparity perspectives and future developments in chemosensitizing activities to reverse drug resistance in gynecologic cancers. It is a valuable resource for cancer researchers, oncologists, clinicians and other biomedical field members who are interested in new approaches to improve chemotherapy outcome in patients with gynecologic cancers. Provides a comprehensive resource with all the details needed for readers to understand and follow information Encompasses schematics, diagrams and flow charts in all chapters to help readers easily follow critical information Presents tables and figures especially developed to summarize the information with appropriate statistical rigor and to show details of clinical specimens such as pathological, radiological characteristics, and/or laboratory biomarkers

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance
Author: Andrew Freywald,Franco Vizeacoumar
Publsiher: Academic Press
Total Pages: 308
Release: 2020-12-04
ISBN 10: 0128213116
ISBN 13: 9780128213117
Language: EN, FR, DE, ES & NL

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance Book Review:

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance, Volume 12, discusses new approaches that are being undertaken to counteract tumor plasticity, understand and tackle the interactions with the microenvironment, and disrupt the rewiring of malignant cells or bypass biological mechanism of resistance by using targeted radionuclide therapies. This book provides a unique opportunity to the reader to understand the fundamental causes of drug resistance and how different approaches are applied. It is a one-stop-shop to understand why it is so difficult to treat cancer, and why only a very few patients respond to therapy and a significant portion develop resistance. Despite a rapid development of more effective anti-cancer drugs and combination therapies, cancer remains the leading cause of lethality in the developed world. The main reason for this is the ability of heterogeneous subpopulations of tumor cells interacting with constantly evolving tumor microenvironment to resist elimination and eventually, trigger cancer relapse. In this book, experts review current concepts explaining molecular and biological mechanisms of cancer drug resistance and discussing advancing approaches for overcoming these therapeutic challenges. Provides the most updated knowledge on the mechanisms of cancer drug resistance and the emerging therapeutic approaches reviewed by experts in the field Brings detailed analyses of most important recently reported developments related to drug resistance and their relevance to overcoming it in cancer patients Discusses in-depth molecular mechanisms and novel concepts of cancer resistance to conventional and advanced therapies

Development of a Patient derived Xenograft Model of Ovarian Cancer to Characterize the Chemotherapy Resistant Population

Development of a Patient derived Xenograft Model of Ovarian Cancer to Characterize the Chemotherapy Resistant Population
Author: Zachary Christopher Dobbin
Publsiher: Unknown
Total Pages: 131
Release: 2014
ISBN 10: 1928374650XXX
ISBN 13: OCLC:976010431
Language: EN, FR, DE, ES & NL

Development of a Patient derived Xenograft Model of Ovarian Cancer to Characterize the Chemotherapy Resistant Population Book Review:

Ovarian cancer while the second most common gynecologic malignancy is the most commons cause of death due to a gynecologic malignancy and the fifth most common cause of death to cancer in women. In 2014, there will be an expected 21,980 cases and 14,270 deaths. Unfortunately, the five-year survival for ovarian cancer is only 40% and this has barely increased over the past 30 years. New approaches need to be developed in order to study ovarian cancer and identify methods of overcoming chemotherapy resistance. This dissertation presents the work conducted in the development of a patient-derived xenograft model of ovarian cancer to characterize the chemotherapy resistant population and identify novel methods of targeting ovarian cancer. The ovarian cancer patient-derived xenograft model recapitulates the heterogeneity of the patients’ tumor and has demonstrated clinical relevance in response to primary therapy. Using RNA-seq, it was identified that ribosomal synthesis was upregulated and targeting RNA Polymerase I is a potential method of overcoming chemotherapy resistance. Using a patient-derived xenograft model provides a novel platform for understanding chemotherapy resistance and recurrence in ovarian cancer.

Ovarian Cancers

Ovarian Cancers
Author: National Academies of Sciences, Engineering, and Medicine,Institute of Medicine,Board on Health Care Services,Committee on the State of the Science in Ovarian Cancer Research
Publsiher: National Academies Press
Total Pages: 396
Release: 2016-05-25
ISBN 10: 0309380464
ISBN 13: 9780309380461
Language: EN, FR, DE, ES & NL

Ovarian Cancers Book Review:

In an era of promising advances in cancer research, there are considerable and even alarming gaps in the fundamental knowledge and understanding of ovarian cancer. Researchers now know that ovarian cancer is not a single disease-several distinct subtypes exist with different origins, risk factors, genetic mutations, biological behaviors, and prognoses. However, persistent questions have impeded progress toward improving the prevention, early detection, treatment, and management of ovarian cancers. Failure to significantly improve morbidity and mortality during the past several decades is likely due to several factors, including the lack of research being performed by specific disease subtype, lack of definitive knowledge of the cell of origin and disease progression, and incomplete understanding of genetic and non-genetic risk factors. Ovarian Cancers examines the state of the science in ovarian cancer research, identifies key gaps in the evidence base and the challenges to addressing those gaps, considers opportunities for advancing ovarian cancer research, and examines avenues for translation and dissemination of new findings and communication of new information to patients and others. This study makes recommendations for public- and private-sector efforts that could facilitate progress in reducing the incidence of morbidity and mortality from ovarian cancers.

Therapeutic Strategies to Overcome ALK Resistance in Cancer

Therapeutic Strategies to Overcome ALK Resistance in Cancer
Author: Luc Friboulet
Publsiher: Academic Press
Total Pages: 216
Release: 2021-01-18
ISBN 10: 0128217790
ISBN 13: 9780128217795
Language: EN, FR, DE, ES & NL

Therapeutic Strategies to Overcome ALK Resistance in Cancer Book Review:

Therapeutic Strategies to Overcome ALK Resistance in Cancer, Volume 13, presents current strategies to improve and prolong clinical benefit in ALK driven cancers. Most patients with ALK-driven cancer are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops. This book discusses topics such as structure and function of ALK, ALK rearranged lung cancer, resistance mechanisms to ALK TKI tumors, and novel therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALCL. Additionally, it encompasses information on drug combinations to enhance ALK TKI anti-tumor efficacy in neuroblastoma and future perspectives in the field. This book is a valuable resource for cancer researchers, clinicians and several members of biomedical field who need to understand more about how to fight ALK resistance in cancer treatment. Explains the biology of ALK RTK, focusing on its tissue expression, structure and functionality Presents an overview of current treatments and the benefits of ALK TKI in lung and other cancer types, such as ALCL, neuroblastoma and inflammatory myofibroblastic tumor Encompasses information on systemic treatments other than TKI, including chemotherapy, immunotherapy and antiangiogenic agents in ALK-driven NSCLC

Surgery for Ovarian Cancer

Surgery for Ovarian Cancer
Author: Robert E. Bristow,Beth Y. Karlan,Dennis S. Chi
Publsiher: CRC Press
Total Pages: 437
Release: 2019-02-21
ISBN 10: 0429578857
ISBN 13: 9780429578854
Language: EN, FR, DE, ES & NL

Surgery for Ovarian Cancer Book Review:

Updated and expanded, the third edition of Surgery for Ovarian Cancer focuses on essential techniques for the effective management of ovarian cancer. It reflects the most contemporary science and surgical applications for the management of patients with ovarian cancer and related peritoneal surface malignancies. This new edition takes a step-by-step approach and includes new intraoperative photographs and videos illustrating surgical procedures. It is principally devoted to the technical aspects of cytoreductive surgery, with chapters divided according to anatomic region. The chapters cover relevant anatomical considerations, surgical challenges specific to each region, and operative approaches and techniques favored by the authors. The list of contributing authors has been expanded from the previous edition and includes international and world-renowned experts from the fields of gynecologic oncology and surgical oncology. The topics of minimally invasive surgery, secondary cytoreduction, palliative surgery, and postoperative care are also covered in detail. New to the third edition are chapters on preoperative risk stratification, regional therapeutics and peritonectomy procedures, and quality assurance relating to ovarian cancer surgery. This comprehensive text is essential reading for all practitioners working with patients with ovarian cancers.

Advances in Epithelial Ovarian Cancer Model Systems Microenvironmental Influences Therapy and Origins

Advances in Epithelial Ovarian Cancer  Model Systems  Microenvironmental Influences  Therapy  and Origins
Author: Viive Maarika Howell,Ben Davidson,TIAN-Li WANG,Christina Annunziata
Publsiher: Frontiers Media SA
Total Pages: 135
Release: 2016-02-03
ISBN 10: 2889197697
ISBN 13: 9782889197699
Language: EN, FR, DE, ES & NL

Advances in Epithelial Ovarian Cancer Model Systems Microenvironmental Influences Therapy and Origins Book Review:

This eBook provides a compendium of the current state-of-the-art in research tools for, and understanding of, the critical research areas in epithelial ovarian cancer (EOC) with a strong emphasis on (HG-SOC). Research areas covered include therapy response and development, microenvironmental influences and the etiology and progression of EOC. Ten articles detail established and novel in vivo and in vitro model systems. These include primary and immortalized cell culture in 2D and 3D as well as genetically engineered, transgenic, spontaneous, syngeneic, classical xenograft and patient derived xenograft mouse models. The generation of genetically engineered mouse models of HG-SOC has been a major dilemma as models with the oncogenic aberrations common in the human malignancy do not accurately recapitulate HG-SOC. Conversely, commonly used HG-SOC cell lines have been found to not harbor the expected genetic changes. These issues as well as the rapid acceptance of patient derived xenograft models are reviewed. Five articles discuss different aspects of the tumor microenvironment including its role in therapy resistance, disease progression and metastasis. Mutation of BRCA1/2 continues to be the best defined risk factor for HG-SOC. Three articles discuss BRCA-loss in the context of disease development, targeted therapies and changes in preventative measures proposed for mutation carriers in light of the recent advances in knowledge regarding the origins of this malignancy. An image of HG-SOC with reduced BRCA1 expression is featured on the cover (image by VM Howell). A major clinical issue for patients with HG-SOC is the development of therapy resistance. Five articles focus on therapy resistance and different ways to overcome resistance. Overall, this eBook is an outstanding resource to aid researchers design their programs of research and determine the most appropriate and up-to-date EOC model systems to address their research questions.

Glioblastoma Resistance to Chemotherapy Molecular Mechanisms and Innovative Reversal Strategies

Glioblastoma Resistance to Chemotherapy  Molecular Mechanisms and Innovative Reversal Strategies
Author: Ramasamy Paulmurugan,Tarik F. Massoud
Publsiher: Academic Press
Total Pages: 828
Release: 2021-06-25
ISBN 10: 0128215682
ISBN 13: 9780128215685
Language: EN, FR, DE, ES & NL

Glioblastoma Resistance to Chemotherapy Molecular Mechanisms and Innovative Reversal Strategies Book Review:

Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies brings current knowledge from an international team of experts on the science and clinical management of glioblastoma chemoresistance. The book discusses topics such as molecular mechanisms of chemoresistance, experimental models to study chemoresistance, chemoresistance to drugs other than Temozolomide, and specific strategies to reverse chemoresistance. Additionally, it encompasses information on how to mitigate chemoresistance by targeted enhancement of p53 function. This book is a valuable resource for cancer researchers, oncologists, neuro-oncologists and other members of the biomedical field. Glioblastoma (GBM) is the most invasive and malignant primary brain tumor in humans with poor survival after diagnosis, therefore it is imperative that molecular and cellular mechanisms behind therapy resistant GBM cells, as well as the therapeutic strategies available to counter the resistance are comprehensively understood. Provides comprehensive, core knowledge related to the entire discipline of glioblastoma chemoresistance, from its many etiological mechanisms, to specific strategies to reverse resistance Presents current information from an international team of experts on the basic science, pre-clinical research, and clinical management of glioblastoma chemoresistance Discusses molecular and cellular mechanisms behind therapy resistant glioblastoma cells, as well as the therapeutic strategies available to counter this resistance

Progress in Cancer Drug Resistance Research

Progress in Cancer Drug Resistance Research
Author: Robert A. Parsons
Publsiher: Nova Publishers
Total Pages: 223
Release: 2007
ISBN 10: 9781600218224
ISBN 13: 1600218229
Language: EN, FR, DE, ES & NL

Progress in Cancer Drug Resistance Research Book Review:

One of the main causes of failure in the treatment of cancer is the development of drug resistance by the cancer cells. The design of cancer chemotherapy has become increasingly sophisticated, yet there is no cancer treatment that is 100 percent effective against disseminated cancer. Resistance to treatment with anticancer drugs results from a variety of factors including individual variations in patients and somatic cell genetic differences in tumours, even those from the same tissue of origin. Frequently resistance is intrinsic to the cancer, but as therapy becomes more and more effective, acquired resistance has also become common.The most common reason for acquisition of resistance to a broad range of anticancer drugs is expression of one or more energy-dependent transporters that detect and eject anti-cancer drugs from cells, but other mechanisms of resistance including insensitivity to drug-induced apoptosis and induction of drug-detoxifying mechanisms probably play an important role in acquired anticancer drug resistance. Studies on mechanisms of cancer drug resistance have yielded important information on how to circumvent this resistance to improve cancer chemotherapy and have implications for pharmacokinetics of many commonly used drugs.

Drug Resistance in Colorectal Cancer Molecular Mechanisms and Therapeutic Strategies

Drug Resistance in Colorectal Cancer  Molecular Mechanisms and Therapeutic Strategies
Author: Chi Hin Cho,Tao Hu
Publsiher: Academic Press
Total Pages: 240
Release: 2020-05-24
ISBN 10: 0128199385
ISBN 13: 9780128199381
Language: EN, FR, DE, ES & NL

Drug Resistance in Colorectal Cancer Molecular Mechanisms and Therapeutic Strategies Book Review:

Drug Resistance in Colorectal Cancer: Molecular Mechanisms and Therapeutic Strategies, Volume Eight, summarizes the molecular mechanisms of drug resistance in colorectal cancer, along with the most up-to-date therapeutic strategies available. The book discusses reasons why colorectal tumors become refractory during the progression of the disease, but also explains how drug resistance occurs during chemotherapy. In addition, users will find the current therapeutic strategies used by clinicians in their practice in treating colorectal cancer. The combination of conventional anticancer drugs with chemotherapy-sensitizing agents plays a pivotal role in improving the outcome of colorectal cancer patients, in particular those with drug-resistant cancer cells. From a clinical point-of-view, the content of this book provides clinicians with updated therapeutic strategies for a better choice of drugs for drug-resistant colorectal cancer patients. It will be a valuable source for cancer researchers, oncologists and several members of biomedical field who are dedicated to better treat patients with colorectal cancer. Presents a systemic summary of molecular mechanisms for a quick and in-depth understanding Updates current trends in the field with pioneering information on drug resistance Encompasses both basic and clinical approaches for a better understanding of unsolved problems from a holistic point-of-view

Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy

Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy
Author: Anonim
Publsiher: Academic Press
Total Pages: 294
Release: 2022-01-26
ISBN 10: 0323905560
ISBN 13: 9780323905565
Language: EN, FR, DE, ES & NL

Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy Book Review:

Anti-angiogenic Drugs as Chemosensitizers in Cancer Therapy, Volume 19 focuses on the use of anti-angiogenic drugs as sensitizers of tumor cells to the inhibitory activity of antitumor agents. Conventional and novel anti-neoplastic agents (cytotoxic molecules, hormones/antihormones, immunotherapies) are taken into consideration, along with advances made in combination therapies. The book encompasses examples of studies on the use of antiangiogenic compounds—molecules that inhibit the growth of vessels inside a tumor—together with antineoplastic drugs in order to sensitize the resistant tumor to their cytotoxic effects, thus reducing adverse side reactions and resistance and improving the therapeutic response of cancer patients. In addition, the book discusses clinical applications in various types of cancer, such as colorectal, lung, breast, renal, genitourinary, skin and brain and circulating tumors. It is a valuable resource for cancer researchers, clinicians and members of the biomedical field who wants to be up-to-date on the most recent and promising developments in the field. Provides the most updated reviews on anti-angiogenic drugs as chemosensitizers by leaders in the field Encompasses summarized tables and schematic diagrams in each chapter to give a clear overview on recent findings in a didactic manner Brings not only relevant information of current research but also new ideas and suggestions for further investigations to help advance the field

Stem Cells

Stem Cells
Author: Suchandra Chowdhury,Shyamasree Ghosh
Publsiher: Springer Nature
Total Pages: 266
Release: 2021-07-24
ISBN 10: 9811616388
ISBN 13: 9789811616389
Language: EN, FR, DE, ES & NL

Stem Cells Book Review:

Stem cells hold great promise for cell therapy, tissue engineering, regenerative medicine and pharmaceutical and biotechnological applications. This book highlights the potency of stem cells, their property of self-renewal and their ability to differentiate into different cell lineages. It further describes the different markers to identify stem cells, sources, methods of isolation, culture including 2D, 3D and beyond and their cryopreservation. This is among the first books to discuss glycosylation and sialylation in stem cells. Chapters describe application of stem cells in regenerative medicine and therapy, and highlight their application in cancer therapy and spinal cord injury. The book talks about the important patents on stem cells. The book also highlights the plant stem cells, discussing their pluoripotent nature, role in organ regeneration after injury, specific stem cell niches, that signals to block differentiation studied in plants shoot, root, and vascular meristems, differentiation of plant stem cell, transcriptional regulation and epigenetic modification of plant stem cells. This book is exciting and cutting edge. It will be of great interest to doctors, students and researchers in the field of regenerative medicine, cancer , biotechnology and plant sciences.

Cancer Drug Resistance Research Perspectives

Cancer Drug Resistance Research Perspectives
Author: Liman S. Torres
Publsiher: Nova Publishers
Total Pages: 223
Release: 2007
ISBN 10: 9781600215728
ISBN 13: 1600215726
Language: EN, FR, DE, ES & NL

Cancer Drug Resistance Research Perspectives Book Review:

One of the main causes of failure in the treatment of cancer is the development of drug resistance by the cancer cells. The design of cancer chemotherapy has become increasingly sophisticated, yet there is no cancer treatment that is 100% effective against disseminated cancer. Resistance to treatment with anticancer drugs results from a variety of factors including individual variations in patients and somatic cell genetic differences in tumours, even those from the same tissue of origin. Frequently resistance is intrinsic to the cancer, but as therapy becomes more and more effective, acquired resistance has also become common. The most common reason for acquisition of resistance to a broad range of anticancer drugs is expression of one or more energy-dependent transporters that detect and eject anticancer drugs from cells, but other mechanisms of resistance including insensitivity to drug-induced apoptosis and induction of drug-detoxifying mechanisms probably play an important role in acquired anticancer drug resistance. Studies on mechanisms of cancer drug resistance have yielded important information about how to circumvent this resistance to improve cancer chemotherapy and have implications for pharmacokinetics of many commonly used drugs. This book presents new and important research in this field.

Sensitization of Cancer Cells for Chemo Immuno Radio therapy

Sensitization of Cancer Cells for Chemo Immuno Radio therapy
Author: Benjamin Bonavida
Publsiher: Springer Science & Business Media
Total Pages: 420
Release: 2008-07-31
ISBN 10: 9781597454742
ISBN 13: 1597454745
Language: EN, FR, DE, ES & NL

Sensitization of Cancer Cells for Chemo Immuno Radio therapy Book Review:

This book reviews novel approaches developed to reverse tumor cell resistance to chemo/immuno/radio-therapy and the use of various sensitizing agents in combination with various cytotoxics. It also introduces several current approaches developed by established investigators that are aimed at overcoming resistance. This is the first volume to compile studies on tumor cell sensitization. It will prove useful for students, scientists, clinicians and pharmaceutical companies.

New Targeting in The Reversal of Resistant Glioblastomas

New Targeting in The Reversal of Resistant Glioblastomas
Author: Ali Syed Arbab
Publsiher: Academic Press
Total Pages: 202
Release: 2021-03-05
ISBN 10: 0128232765
ISBN 13: 9780128232767
Language: EN, FR, DE, ES & NL

New Targeting in The Reversal of Resistant Glioblastomas Book Review:

New Targeting in The Reversal of Resistant Glioblastomas discusses alternative treatment strategies that not only target tumor cells but also target the tumor microenvironment, metabolic pathways and interaction of cytokines in tumor cells. The current treatment for primary and recurrent glioblastomas is failing because clinicians are not considering the effect of bone marrow derived cells to the development of resistance to clinically practiced therapies. This book helps readers rethink treatment strategies to successfully fight glioblastomas. It is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field. Explains the effect of bone marrow derived cells on the development of resistance to clinically practiced therapies Provides information on the availability of alternate therapies for recurrent glioblastoma when standard practices have failed Discusses targeting tumor microenvironment using available FDA approved drugs as an alternative treatment strategy for glioblastoma